Abstract | UNLABELLED: RESULTS: A total of 138 patients were randomised. 13 patients were excluded later. The two groups were comparable regarding age, sex, weight and diagnosis. The average treatment lasted 8.3 (5-26) days in the LMWH-group and 7.4 (4-14) days in the heparine-group. The average hospital stay was 10.4 days in the LMWH-group, and 11.0 days in the heparine-group. The complication rate was 5 (3.1%) (5 events: 3 hemorrhages, 1 reembolism, 1 death) in the LMWH-group and 4 (2.5%) (4 events: 3 bleedings, 1 sepsis of the venous catheter) in the heparine-group. We found no significant outcome difference between the two treatment groups. CONCLUSION: Weight-adapted (200 IE/kg/day) subcutaneous application of Dalteparin once daily in the treatment of patients with deep venous thrombosis or lung embolism is as safe as intravenous treatment with unfragmented heparine.
|
Authors | R Häfeli, S Kraljevic, C Wehrli, J Goede, D Conen |
Journal | Praxis
(Praxis (Bern 1994))
Vol. 90
Issue 33
Pg. 1339-45
(Aug 16 2001)
ISSN: 1661-8157 [Print] Switzerland |
Vernacular Title | Nieder-molekulares Heparin (Dalteparin) in der Behandlung von Patienten mit thromboembolischen (TVT/LE) Ereignissen. |
PMID | 11534317
(Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Aged
- Dalteparin
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Heparin
(administration & dosage, adverse effects)
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- Recurrence
- Thromboembolism
(drug therapy)
|